In the realm of mental health innovation, Compass Pathways plc (CMPS) is recalibrating its clinical and regulatory trajectory with a decisive acceleration in its commercialization timeline.
The company recently announced a 9-12 month acceleration in its commercialization readiness plans for COMP360, its investigational psilocybin therapy for treatment-resistant depression (TRD). This strategic pivot follows a completed Phase 3 trial (COMP006) enrollment and favorable FDA feedback on submission strategy, including the potential for rolling NDA review.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com